Pfizer drug acquired in Seagen deal disappoints in lung cancer study
BioPharma Dive
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug s chances in another trial.
pharminent
June 23, 2026 (Last updated: June 24, 2026)
BioPharma Dive
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug s chances in another trial.